1H-吲哚-7-羧酸甲酯 | 93247-78-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1H-吲哚-7-羧酸甲酯
• 中文别名: 吲哚-7-羧酸甲酯；吲哚-7-甲酸甲酯
• 英文名称: methyl 1H-indole-7-carboxylate
• 英文别名: methyl indole-7-carboxylate；indole-7-carboxylic acid methyl ester；1H-Indole-7-carboxylic acid,methyl ester
• CAS: 93247-78-0
• 化学式: C₁₀H₉NO₂
• mdl: MFCD00211064
• 分子量: 175.187
• InChiKey: FTLOEULOTNVCGF-UHFFFAOYSA-N

物化性质

• 熔点：
  47-48°C
• 沸点：
  331.7±15.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 安全说明：
  S26,S36/37/39,S37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Name:	Methyl 1H-indole-7-carboxylate, 97% Material Safety Data Sheet
Synonym:
CAS:	93247-78-0

Section 1 - Chemical Product MSDS Name: Methyl 1H-indole-7-carboxylate, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
93247-78-0	Methyl 1H-indole-7-carboxylate	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 93247-78-0: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 47 - 48 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9NO2
Molecular Weight: 175.19

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 93247-78-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 1H-indole-7-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 93247-78-0: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 93247-78-0 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 93247-78-0 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/03/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1H-吲哚-7-羧酸甲酯 在 10 wt% Pd(OH)2 on carbon 、 氢气 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 3-甲基-1H-吲哚-7-羧酸甲酯
  参考文献：
  名称：

  设计和合成2,2'-二吲哚甲烷甲烷以选择性靶向某些G-四链体DNA结构

  摘要：

  G-四链体（G4）结构具有重要的生物学功能，选择性靶向某些G4结构的化合物具有治疗潜力和作为研究工具的价值。沿着这条路线，在3,6-或3,7-二取代的吲哚与醛的缩合反应基础上，设计并合成了2,2'-二吲哚基甲烷。已开发的一类化合物可有效稳定G4结构，而不会引起此类结构的构象变化。此外，2,2'-二吲哚基甲烷比其他某些更有效地靶向某些G4结构，并且该G4选择性可以通过化合物的化学修饰来改变。

  DOI：

  10.1002/chem.201602416
• 作为产物：
  描述：

  3-甲基-2-硝基苯甲酸甲酯 在 palladium on activated charcoal 氢气 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 1H-吲哚-7-羧酸甲酯
  参考文献：
  名称：

  Thromboxane A2 Synthetase Inhibitors with Histamine H1-Blocking Activity: Synthesis and Evaluation of a New Series of Indole Derivatives.

  摘要：

  制备了一系列N-取代的3-(1H-咪唑-1-基甲基)吲哚羧酸衍生物，并评估了它们对血栓素A2（TXA2）合成酶抑制和组胺H1受体阻断的活性。在合成的化合物中，6-吲哚羧酸衍生物显示出比其他位置异构体更高的活性。1-[3-(4-苯并氢吡啶-1-基)丙基]-3-(1H-咪唑-1-基甲基)-1H-吲哚-6-羧酸（12）具有最强的血栓素合成酶抑制活性（IC50=5×10-8M）和H1受体阻断活性（IC50=8×10-9M）。

  DOI：

  10.1248/cpb.43.1692

文献信息

• Structure–Activity Relationship in Pyrazolo[4,3-<i>c</i>]pyridines, First Inhibitors of PEX14–PEX5 Protein–Protein Interaction with Trypanocidal Activity
  作者：Maciej Dawidowski、Vishal C. Kalel、Valeria Napolitano、Roberto Fino、Kenji Schorpp、Leonidas Emmanouilidis、Dominik Lenhart、Michael Ostertag、Marcel Kaiser、Marta Kolonko、Bettina Tippler、Wolfgang Schliebs、Grzegorz Dubin、Pascal Mäser、Igor V. Tetko、Kamyar Hadian、Oliver Plettenburg、Ralf Erdmann、Michael Sattler、Grzegorz M. Popowicz

  DOI：10.1021/acs.jmedchem.9b01876

  日期：2020.1.23

  PEX14-PEX5 protein-protein interaction (PPI) is an attractive way to affect multiple metabolic pathways. Herein, we have used structure-guided computational screening and optimization to develop the first line of compounds that inhibit PEX14-PEX5 PPI. The optimization was driven by several X-ray structures, NMR binding data, and molecular dynamics simulations. Importantly, the developed compounds show

  锥虫的原生生物是导致一系列毁灭性传染病的病原体。针对锥虫的可用化学疗法的范围是有限的，并且现有疗法部分无效并且会引起严重的不良反应。PEX14-PEX5复合物的形成对于将蛋白质导入寄生虫的糖体至关重要。这种运输对寄生虫的代谢至关重要，失败会导致糖体酶的错误定位，并对寄生虫造成致命的后果。因此，抑制PEX14-PEX5蛋白-蛋白相互作用（PPI）是影响多种代谢途径的一种有吸引力的方法。在本文中，我们已使用结构指导的计算筛选和优化方法来开发抑制PEX14-PEX5 PPI的第一类化合物。优化是由几个X射线结构，NMR结合数据，和分子动力学模拟。重要的是，已开发的化合物对锥虫具有显着的细胞活性，包括人类病原体布鲁氏冈比亚锥虫和克氏锥虫寄生虫。
• Sulfonamide peri-substituted bicyclics for occlusive artery disease
  申请人：Singh Jasbir

  公开号：US20060079520A1

  公开（公告）日：2006-04-13

  Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

  酰基磺酰胺，带有周取代的融合双环环化合物，用于治疗或预防前列腺素介导的疾病或症状。这些化合物的一般公式为 代表性示例是：
• [EN] BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS BICYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：TEMPEST THERAPEUTICS INC

  公开号：WO2018195123A1

  公开（公告）日：2018-10-25

  The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.

  本公开涉及一种新型化合物I的化学式及其药用可接受的盐、溶剂化合物、盐的溶剂化合物和前药，用于预防（例如，延迟发病或减少发展风险）和治疗（例如，控制、缓解或减缓进展）癌症，包括胶质母细胞瘤、骨癌、头颈癌、黑色素瘤、基底细胞癌、鳞状细胞癌、腺癌、口腔癌、食管癌、胃癌、肠癌、结肠癌、膀胱癌、肝细胞癌、肾细胞癌、胰腺癌、卵巢癌、宫颈癌、肺癌、乳腺癌和前列腺癌。本公开的化合物是EP4受体的选择性拮抗剂，可用于治疗多种疾病，这些疾病可能通过阻断PGE2介导的信号传导而得到缓解。
• Iron-Catalyzed Intermolecular 1,2-Difunctionalization of Styrenes and Conjugated Alkenes with Silanes and Nucleophiles
  作者：Yuan Yang、Ren-Jie Song、Xuan-Hui Ouyang、Cheng-Yong Wang、Jin-Heng Li、Shenglian Luo

  DOI：10.1002/anie.201702349

  日期：2017.6.26

  The first iron‐catalyzed 1,2‐difunctionalization of styrenes and conjugated alkenes with silanes and either N or C, using an oxidative radical strategy, is described. Employing FeCl2 and di‐tert‐butyl peroxide allows divergent alkene 1,2‐difunctionalizations, including 1,2‐aminosilylation, 1,2‐arylsilylation, and 1,2‐alkylsilylation, which rely on a wide range of nucleophiles, namely, amines, amides

  描述了使用氧化自由基策略的首次铁催化的苯乙烯和共轭烯烃与硅烷以及N或C的1,2-双官能化。使用FeCl 2和二叔丁基过氧化物可以实现不同的烯烃1,2-双官能化，包括1,2-氨基甲硅烷基化，1,2-芳基甲硅烷基化和1,2-烷基甲硅烷基化，它们依赖于广泛的亲核试剂，即胺，酰胺，吲哚，吡咯和1,3-二羰基化合物，因此为生产各种含硅烷烃提供了强大的平台。
• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。